NVAXNovavax, Inc.

$12.74+46% 1Y
Latest close: a new 52-week highOct 9, 2026what changed →

Is the price fair?

What NVAX's price assumes

Novavax, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 3.40× revenue.

3.40

Price / sales · no P/E: the last twelve months did not end in a profit

EV / sales
2.37

EV / sales

Details›
EV / EBIToperating margin −57%: the multiple describes the denominator
not meaningful
EV / salestoday's price, trailing year to Jun 30, 2026
2.37
Market capitalisation
$1.41B

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

On our screens:Most shorted stocks